PDRN (polydeoxyribonucleotide) — purified DNA fragments derived from salmon sperm cells — has become the breakout ingredient story of Korean aesthetic medicine. Injectable PDRN, marketed as Rejuran, has been a clinic staple since the late 2010s. The 2024–2026 development is the rapid expansion of topical PDRN — ampoules, toner pads, and creams that aim to deliver PDRN-like signaling without injections. This blog walks through what each form actually does and how Korean clinics are integrating both.
What PDRN actually is
PDRN consists of fragments of DNA, typically 50–1500 base pairs in length, purified from salmon sperm. The biology rationale: salmon DNA shares enough structural similarity with human DNA that the fragments bind to A2A adenosine receptors on human fibroblasts. This binding triggers:
- Increased fibroblast activity and collagen production.
- Enhanced angiogenesis (new blood vessel formation).
- Anti-inflammatory signaling.
- Improved skin barrier function.
The mechanism is real and has been reasonably characterized in Korean dermatology research over a decade. The unresolved question is the magnitude of effect at different doses and routes.
Injectable PDRN — the Rejuran family
The Rejuran product family covers several formulations for different indications:
- Rejuran S — original formulation, used widely for skin barrier repair, post-acne scarring, and overall skin quality.
- Rejuran I — concentrated formulation designed for thinner skin (under-eye, lips).
- Rejuran HB — hyaluronic-acid-enhanced version, combining PDRN with hydration.
Standard protocol: 3–4 sessions, 2–4 weeks apart, with maintenance every 6–12 months. Reasonably consistent improvement in skin quality, barrier function, and scarring.
Topical PDRN — the 2024–2026 expansion
The historical limitation: PDRN molecules are large enough that simple topical application doesn\'t penetrate effectively. Recent Korean formulations have addressed this with several approaches:
- Low-molecular-weight PDRN — fragmenting PDRN into smaller chains capable of penetrating the stratum corneum.
- Liposomal delivery — encapsulating PDRN in lipid carriers for skin delivery.
- Microneedle pads — physical disruption of skin barrier to enable PDRN penetration.
- Synergistic formulations — pairing PDRN with peptides, hyaluronic acid, and barrier-supporting actives.
Multiple Korean brands now market PDRN serums and creams. Effectiveness varies dramatically with formulation quality and delivery system.
Topical vs. injectable — what each actually delivers
| Aspect | Topical PDRN | Injectable Rejuran |
|---|---|---|
| Penetration depth | Surface to upper dermis | Mid to deep dermis |
| Onset | Weeks of consistent use | Visible after 2nd session |
| Best for | Maintenance, skin quality, barrier | Targeted scar/quality remodeling |
| Cost (Korean derm 2026) | $30–$100 per product | $300–$600 per session |
| Downtime | None | 2–4 days mild bumps |
Where the evidence is strongest
- Injectable PDRN for skin quality and barrier repair — multiple Korean clinical studies show measurable improvement.
- Injectable PDRN for early acne scarring — reasonable evidence as part of combination protocols.
- Injectable PDRN for radiation-damaged skin — historical use case in oncology dermatology.
- Topical PDRN for skin barrier and texture — emerging evidence; product quality variability is the limiting factor.
Where claims outpace evidence
- "Stem-cell-like" claims around topical PDRN — mechanism is collagen-stimulation, not stem-cell biology.
- "Anti-aging miracle" framing — PDRN is one tool among many, not a transformative monotherapy.
- Hair-growth claims for topical PDRN — limited evidence vs. injectable applications.
How Korean clinics actually use PDRN in 2026
The mature 2026 protocol typically combines:
- Injectable Rejuran sessions 3–4 times annually for active concerns or every 6–12 months for maintenance.
- Topical PDRN home care daily as part of the home routine.
- Pico toning, light HIFU, and other modalities sequenced around PDRN protocol.
- Post-laser PDRN topicals as part of healing support after fractional laser, RF microneedling, etc.
Patient profiles that benefit most
- Sensitive or reactive skin needing barrier support.
- Post-acne skin texture and pigmentation concerns.
- Thin under-eye skin (Rejuran I specifically).
- Patients in their 30s and 40s wanting subtle quality improvement.
- Post-procedure healing support.
Where PDRN underdelivers
- Deep static wrinkles — these need volume, lasers, or surgery.
- Significant skin laxity — devices and surgery, not PDRN.
- Active acne — antibiotic and retinoid management, not skin booster.
- Severe photoaging — fractional laser or peel, with PDRN as adjunct.
What to look for in topical PDRN products
- Specific PDRN concentration disclosed (preferably with molecular weight information).
- Reputable Korean brand with regulatory documentation.
- Pairing with skin-barrier supporting actives (ceramides, hyaluronic acid).
- No "stem cell" or "exosome" claims that conflict with the 2025 MFDS marketing rules.
- Clinical-trial backing where available.
The honest framing
Injectable PDRN earned its reputation through consistent results in skin quality and barrier repair. Topical PDRN is a real category with real value when formulated well — and a marketing trap when formulated poorly. The 2026 Korean approach treats them as complementary: injectable for the structural work, topical for the daily maintenance. Patients who pick the right combination get the most out of both.